

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/129697 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *C12N 15/13* (2006.01)
- (21) **International Application Number:**
PCT/CN2020/138800
- (22) **International Filing Date:**
24 December 2020 (24.12.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/CN2019/127915
24 December 2019 (24.12.2019) CN
- (71) **Applicant:** LANOVA MEDICINES LIMITED COMPANY [CN/CN]; 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 (CN).
- (72) **Inventor:** LI, Runsheng; 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza, Shanghai 201203 (CN).
- (74) **Agent:** SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM; Room 25A 3-1, East Wing, Hanwei Plaza No. 7 Guanghua Road, Chaoyang District, Beijing 100020 (CN).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ANTI-SIRPα MONOCLONAL ANTIBODIES AND USES THEREOF

(57) **Abstract:** Provided are antibodies or fragments thereof having binding specificity to both variant 1 and variant 2 of the signal regulatory protein alpha (SIRPα) protein. The antibodies and fragments can dose-dependently and efficiently block the interaction between SIRPα and CD47, and effectively induce macrophage-mediated phagocytosis of tumor cells expressing CD47.



WO 2021/129697 A1